Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome

Translational Research

Volumn 166, Issue 2, 2015, Pages 207-217

  Koelzer, Viktor H ^a,b   Dawson, Heather ^a,b   Andersson, Emilia ^a,b   Karamitopoulou, Eva ^a,b   Masucci, Giuseppe V ^a,b   Lugli, Alessandro ^a,b   Zlobec, Inti ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD8 ANTIGEN; RNA BINDING PROTEIN; HLA ANTIGEN CLASS 1; IMMUNOLOGICAL ADJUVANT; POLYADENYLIC ACID BINDING PROTEIN; TIA1 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ARTICLE; CELL BUDDING; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOSURVEILLANCE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR BUDDING; TUMOR INVASION; TUMOR MICROENVIRONMENT; CD8+ T LYMPHOCYTE; COLORECTAL NEOPLASMS; DRUG EFFECTS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; MULTIVARIATE ANALYSIS; POLY(A)-BINDING PROTEINS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84937643618     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.02.008     Document Type: Article

References (35)

1. N.F. Watson, J.M. Ramage, Z. Madjd, and et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis Int J Cancer 118 2006 6 10
2. J.A. Simpson, A. Al-Attar, N.F. Watson, J.H. Scholefield, M. Ilyas, and L.G. Durrant Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer Gut 59 2010 926 933
3. I. Zlobec, E. Karamitopoulou, L. Terracciano, and et al. TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer PLoS One 5 2010 e14282
4. J. Galon, A. Costes, F. Sanchez-Cabo, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
5. B. Mlecnik, M. Tosolini, A. Kirilovsky, and et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction J Clin Oncol 29 2011 610 618
6. A. Kasajima, C. Sers, H. Sasano, and et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer Hum Pathol 41 2010 1758 1769
7. A.G. Grandea 3rd, M.J. Androlewicz, R.S. Athwal, D.E. Geraghty, and T. Spies Dependence of peptide binding by MHC class I molecules on their interaction with TAP Science 270 1995 105 108
8. C.M. Cabrera, P. Jimenez, T. Cabrera, C. Esparza, F. Ruiz-Cabello, and F. Garrido Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors Tissue Antigens 61 2003 211 219
9. J.W. Dierssen, N.F. de Miranda, S. Ferrone, and et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression BMC Cancer 7 2007 33
10. D. Atkins, A. Breuckmann, G.E. Schmahl, and et al. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma Int J Cancer 109 2004 265 273
11. E.M. Tomazou, V.K. Rakyan, G. Lefebvre, and et al. Generation of a genomic tiling array of the human major histocompatibility complex (MHC) and its application for DNA methylation analysis BMC Med Genomics 1 2008 19
12. I. Zlobec, and A. Lugli Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget Oncotarget 1 2010 651 661
13. M. Horcic, V.H. Koelzer, E. Karamitopoulou, and et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer Hum Pathol 44 2013 697 705
14. I. Zlobec, M.P. Bihl, A. Foerster, A. Rufle, and A. Lugli The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer Histopathology 61 2012 777 787
15. A. Lugli, E. Karamitopoulou, I. Panayiotides, and et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer Br J Cancer 101 2009 1382 1392
16. S. Popat, and R.S. Houlston Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1855 author reply 6
17. E. Karamitopoulou, I. Zlobec, V. Kolzer, and et al. Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer Mod Pathol 26 2013 295 301
18. V.H. Koelzer, E. Karamitopoulou, H. Dawson, A. Kondi-Pafiti, I. Zlobec, and A. Lugli Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer Br J Cancer 108 2013 2088 2096
19. V.H. Koelzer, K. Baker, D. Kassahn, D. Baumhoer, and I. Zlobec Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status J Clin Pathol 65 2012 996 1002
20. E. Andersson, L. Villabona, K. Bergfeldt, and et al. Correlation of HLA-A02∗genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer Cancer Immunol Immunother 61 2012 1243 1253
21. L.A. Lampson, C.A. Fisher, and J.P. Whelan Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines J Immunol 130 1983 2471 2478
22. F. Perosa, G. Luccarelli, M. Prete, E. Favoino, S. Ferrone, and F. Dammacco Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide J Immunol 171 2003 1918 1926
23. M.F. Sernee, H.L. Ploegh, and D.J. Schust Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents Mol Immunol 35 1998 177 188
24. N.J. Stam, H. Spits, and H.L. Ploegh Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products J Immunol 137 1986 2299 2306
25. A. Zhang, H. Yu, Y. He, and et al. The spatio-temporal expression of MHC class I molecules during human hippocampal formation development Brain Res 1529 2013 26 38
26. I. Zlobec, K. Baker, L. Terracciano, and et al. Two-marker protein profile predicts poor prognosis in patients with early rectal cancer Br J Cancer 99 2008 1712 1717
27. H. Dawson, J.A. Galvan, M. Helbling, and et al. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency Int J Cancer 134 2014 2342 2351
28. J. Galon, B. Mlecnik, G. Bindea, and et al. Towards the introduction of the 'immunoscore' in the classification of malignant tumours J Pathol 232 2014 199 209
29. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
30. R. Tallerico, M. Todaro, S. Di Franco, and et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules J Immunol 190 2013 2381 2390
31. N. Halama, M. Braun, C. Kahlert, and et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines Clin Cancer Res 17 2011 678 689
32. W.H. Fridman, F. Pages, C. Sautes-Fridman, and J. Galon The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 2012 298 306
33. M.R. Oliva, T. Cabrera, J. Esquivias, and et al. K-ras mutations (codon 12) are not involved in down-regulation of MHC class-I genes in colon carcinomas Int J Cancer 46 1990 426 431
34. I. Zlobec, M. Kovac, P. Erzberger, and et al. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer Int J Cancer 127 2010 2569 2575
35. M. Donia, P. Fagone, F. Nicoletti, and et al. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer Oncoimmunology 1 2012 1476 1483